HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating for Ventyx Biosciences (NASDAQ:VTYX) and maintained a $6 price target.
October 15, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Ventyx Biosciences with a maintained price target of $6, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $6 price target suggests that the analyst does not foresee significant changes in the stock's performance in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100